Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-2p87r Total loading time: 0.173 Render date: 2021-10-21T12:09:55.216Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Modafinil for the Treatment of Fatigue in Multiple Sclerosis

Published online by Cambridge University Press:  15 February 2006

Bruno Stankoff
Affiliation:
Centre d'Investigation Clinique, Hopital Pitié-Salpêtrière, Paris, France Service de Pharmacologie, Hopital Pitié-Salpêtrière, Paris, France; Email: bruno.stankoff@psl.ap-hop-paris.fr
Catherine Lubetzki
Affiliation:
Fédération de Neurologie, Hopital Pitié-Salpêtrière, Paris, France; Email: catherine.lubetzki@psl.ap-hop-paris.fr
Michel Clanet
Affiliation:
Fédération de Neurologie, CHU de Toulouse, France; Email: clanet@cict.fr

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Review Article
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Banerjee, D., Vitiello, M.V., & Grunstein, R.R. (2004). Pharmacotherapy for excessive daytime sleepiness. Sleep Medicine Reviews, 8 (5), 339354.Google Scholar
Bever, Jr., C.T., Young, D., Anderson, P.A., Krumholz, A., Conway, K., Leslie, J., et al. (1994). The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology, 44 (6), 10541059.Google Scholar
Bever, Jr., C.T., Anderson, P.A., Leslie, J., Panitch, H.S., Dhib-Jalbut, S., Khan, O.A. et al. (1996). Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology, 47 (6), 14571462.Google Scholar
The Canadian MS Research Group. (1987). A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Canadian Journal of Neurological Sciences, 14 (3), 273278.Google Scholar
Cohen, R.A., & Fisher, M. (1989). Amantadine treatment of fatigue associated with multiple sclerosis. Archives of Neurology, 46 (6), 676680.Google Scholar
Comi, G., Leocani, L., Rossi, P., & Colombo, B. (2001). Physiopathology and treatment of fatigue in multiple sclerosis. Journal of Neurology, 248 (3), 174179.Google Scholar
Filippi, M., Rocca, M.A., Colombo, B., Falini, A., Codella, M., Scotti, G., et al. (2002). Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage, 15 (3), 559567.Google Scholar
Fisk, J.D., Pontefract, A., Ritvo, P.G., Archibald, C.J., & Murray, T.J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21 (1), 914.Google Scholar
Krupp, L.B., Coyle, P.K., Doscher, C., Miller, A., Cross, A.H., Jandorf, L., et al. (1995). Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology, 45 (11), 19561961.Google Scholar
Lin, J.S., Hou, Y., & Jouvet, M. (1996). Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proceedings of the National Academy of Sciences of the United States of America, 93 (24), 1412814133.Google Scholar
Mathew, N.T., Saper, J.R., Silberstein, S.D., Rankin, L., Markley, H.G., Solomon, S., et al. (1995). Migraine prophylaxis with divalproex. Archives of Neurology, 52 (3), 281286.Google Scholar
Murray, T.J. (1985). Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences, 12 (3), 251254.Google Scholar
Oken, B.S., Kishiyama, S., Zajdel, D., Bourdette, D., Carlsen, J., Haas, M., et al. (2004). Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology, 62 (11), 20582064.Google Scholar
Polman, C.H., Bertelsmann, F.W., van Loenen, A.C., & Koetsier, J.C. (1994a). 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Archives of Neurology, 51 (3), 292296.Google Scholar
Polman, C.H., Bertelsmann, F.W., de Waal, R., van Diemen, H.A., Uitdehaag, B.M., van Loenen, A.C., et al. (1994b). 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Archives of Neurology, 51 (11), 11361139.Google Scholar
Rammohan, K.W., Rosenberg, J.H., Lynn, D.J., Blumenfeld, A.M., Pollak, C.P., & Nagaraja, H.N. (2002). Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. Journal of Neurology Neurosurgery and Psychiatry, 72 (2), 179183.Google Scholar
Ritvo, P.G., Fisk, J.D., Archibald, C.J., Murray, T.J., & Field, C. (1996). Psychosocial and neurological predictors of mental health in multiple sclerosis patients. Journal of Clinical Epidemiology, 49 (4), 467472.Google Scholar
Rossini, P.M., Pasqualetti, P., Pozzilli, C., Grasso, M.G., Millefiorini, E., Graceffa, A., et al. (2001). Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Multiple Sclerosis, 7 (6), 354358.Google Scholar
Roelcke, U., Kappos, L., Lechner-Scott, J., Brunnschweiler, H., Huber, S., Ammann, W., et al. (1997). Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology, 48 (6), 15661571.Google Scholar
Scammell, T.E., Estabrooke, I.V., McCarthy, M.T., Chemelli, R.M., Yanagisawa, M., Miller, M.S., et al. (2000). Hypothalamic arousal regions are activated during modafinil-induced wakefulness. Journal of Neuroscience, 20 (22), 86208628.Google Scholar
Schwartz, C.E., Coulthard-Morris, L., & Zeng, Q. (1996). Psychosocial correlates of fatigue in multiple sclerosis. Archives of Physical Medicine and Rehabilitation, 77 (2), 165170.Google Scholar
Sheean, G.L., Murray, N.M., Rothwell, J.C., Miller, D.H., & Thompson, A.J. (1998). An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain, 121, 967975.Google Scholar
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., et al. (2005). French modafinil study group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology, 64, 11391143.Google Scholar
Tomassini, V., Pozzilli, C., Onesti, E., Pasqualetti, P., Marinelli, F., Pisani, A., et al. (2004). Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. Journal of Neurological Sciences, 218 (1–2), 103108.Google Scholar
Van Diemen, H.A., Polman, C.H., van Dongen, T.M., van Loenen, A.C., Nauta, J.J., Taphoorn, M.J., et al. (1992). The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Annals of Neurology, 32 (2), 123130.Google Scholar
Weinshenker, B.G., Penman, M., Bass, B., Ebers, G.C., & Rice, G.P. (1992). A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology, 42 (8), 14681471.Google Scholar
Wingerchuk, D.M., Benarroch, E.E., O'Brien, P.C., Keegan, B.M., Lucchinetti, C.F., Noseworthy, J.H., et al. (2005). A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology, 64 (7), 12671269.Google Scholar
Wisor, J.P., & Eriksson, K.S. (2005). Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience, 132 (4), 10271034.Google Scholar
Zifko, U.A., Rupp, M., Schwarz, S., Zipko, H.T., & Maida, E.M. (2002). Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. Journal of Neurology, 249 (8), 983987Google Scholar

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Modafinil for the Treatment of Fatigue in Multiple Sclerosis
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Modafinil for the Treatment of Fatigue in Multiple Sclerosis
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Modafinil for the Treatment of Fatigue in Multiple Sclerosis
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *